Johnlee Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.00 Cr
- Revenue Growth 24.50%
- Profit Growth 61.70%
- Ebitda 40.98%
- Net Worth 60.87%
- Total Assets 17.54%
About Johnlee Pharmaceuticals
Johnlee Pharmaceuticals Private Limited (JPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 25 April 2011 and has a history of 13 years and nine months. Its registered office is in Mumbai, Maharashtra, India.
The Corporate was formerly known as Jsk Medicare Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹6.00 Cr.
Dilip Jain and Girish Jain serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U46300MH2011PTC216610
-
Company No.
216610
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 Apr 2011
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Johnlee Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dilip Jain
|
Director | 25-Apr-2011 | Current |
|
Girish Jain
|
Director | 25-Apr-2011 | Current |
Financial Performance of Johnlee Pharmaceuticals.
Johnlee Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 24.5% increase. The company also saw a substantial improvement in profitability, with a 61.7% increase in profit. The company's net worth Soared by an impressive increase of 60.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Johnlee Pharmaceuticals?
In 2023, Johnlee Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Genericplus Pharmacy Private LimitedGirish Jain is a mutual person
Charges (Loans)
₹60.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 6.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Aug 2018 | Others | ₹6.00 Cr | Open |
How Many Employees Work at Johnlee Pharmaceuticals?
Unlock and access historical data on people associated with Johnlee Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Johnlee Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Johnlee Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.